MCID: CNT018
MIFTS: 37

Central Nervous System Leukemia malady

Categories: Cancer diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Leukemia

Aliases & Descriptions for Central Nervous System Leukemia:

Name: Central Nervous System Leukemia 12 14 69
Leukemia of the Cns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12969
NCIt 47 C5440
UMLS 69 C1332884

Summaries for Central Nervous System Leukemia

Disease Ontology : 12 A hematologic cancer located in the central nervous system.

MalaCards based summary : Central Nervous System Leukemia, also known as leukemia of the cns, is related to leukemia and mixed germ cell cancer. An important gene associated with Central Nervous System Leukemia is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and NF-kappaB Signaling. The drugs Cytarabine and Daunorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and brain, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and integument

Related Diseases for Central Nervous System Leukemia

Graphical network of the top 20 diseases related to Central Nervous System Leukemia:



Diseases related to Central Nervous System Leukemia

Symptoms & Phenotypes for Central Nervous System Leukemia

GenomeRNAi Phenotypes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.92 MME PBX1 RUNX1 RUNX1T1

MGI Mouse Phenotypes related to Central Nervous System Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.55 CD19 MME PBX1 RUNX1 RUNX1T1
2 liver/biliary system MP:0005370 9.26 CD19 MME PBX1 RUNX1
3 normal MP:0002873 8.92 CD19 PBX1 RUNX1 RUNX1T1

Drugs & Therapeutics for Central Nervous System Leukemia

Drugs for Central Nervous System Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 530)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 147-94-4 6253
2
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 20830-81-3 30323
3
Idarubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 58957-92-9 42890
4
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 170729-80-3 151165 6918365
6
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1 172673-20-0 219090
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
11
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
14
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
15
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
16
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
17
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
18
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 4291-63-8 20279
19
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
20
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
21
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
22
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
23
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
24
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
25
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
26
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
27
Teniposide Approved Phase 4,Phase 2 29767-20-2 34698
28
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Early Phase 1 3778-73-2 3690
29
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
30
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
31
Nitric Oxide Approved Phase 4 10102-43-9 145068
32
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
33
Prilocaine Approved Phase 4 721-50-6 4906
34
Amsacrine Approved Phase 4,Phase 3,Phase 2 51264-14-3 2179
35
Nicotine Approved Phase 4,Phase 3 54-11-5 942 89594
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
37
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
38
Substance P Investigational Phase 4,Phase 3,Phase 2,Phase 1 33507-63-0 44359816
39
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
40
Butyric Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 645)
id Name Status NCT ID Phase
1 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4
2 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4
3 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
4 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
5 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4
6 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4
7 Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy Completed NCT01094990 Phase 4
8 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
9 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4
10 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4
11 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
12 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4
13 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4
14 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Recruiting NCT02894645 Phase 4
15 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Recruiting NCT00846703 Phase 4
16 PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4
17 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
18 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Active, not recruiting NCT00853008 Phase 4
19 Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Unknown status NCT00199108 Phase 2, Phase 3
20 Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3
21 Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors Unknown status NCT00278239 Phase 3
22 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
23 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
24 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
25 Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients Unknown status NCT01333358 Phase 3
26 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia Unknown status NCT00002701 Phase 3
27 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3
28 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3
29 Treatment of Acute Lymphoblastic Leukemia in Children Unknown status NCT00400946 Phase 3
30 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3
31 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3
32 Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia Completed NCT00795756 Phase 2, Phase 3
33 Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain Completed NCT00293358 Phase 3
34 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00005596 Phase 3
35 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
36 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
37 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
38 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
39 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
40 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
41 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
42 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
43 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
44 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
45 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3
46 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3
47 Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia Completed NCT00003991 Phase 3
48 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3
49 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3
50 Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission Completed NCT00002534 Phase 3

Search NIH Clinical Center for Central Nervous System Leukemia

Genetic Tests for Central Nervous System Leukemia

Anatomical Context for Central Nervous System Leukemia

MalaCards organs/tissues related to Central Nervous System Leukemia:

39
Bone, Myeloid, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Leukemia:

18
The Central Nervous System

Publications for Central Nervous System Leukemia

Articles related to Central Nervous System Leukemia:

(show top 50) (show all 64)
id Title Authors Year
1
Comprehensive craniospinal radiation for controlling central nervous system leukemia. ( 25539370 )
2014
2
Establishment of NOD/SCID mouse model of central nervous system leukemia. ( 24927394 )
2014
3
Predictive role of cerebrospinal fluid hydrogen sulfide in central nervous system leukemia. ( 22340157 )
2011
4
Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia? ( 21398042 )
2011
5
Controversies in the management of central nervous system leukemia. ( 20469977 )
2010
6
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. ( 18661773 )
2008
7
Central nervous system leukemia on magnetic resonance imaging. ( 18310989 )
2008
8
Primary central nervous system leukemia presenting with an isolated oculomotor palsy. ( 18710807 )
2008
9
Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. ( 17487757 )
2007
10
Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. ( 17924103 )
2007
11
Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction. ( 15681484 )
2005
12
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. ( 14581336 )
2003
13
Bilateral optic nerve infiltration in central nervous system leukemia. ( 12504706 )
2003
14
Central nervous system leukemia recurring over more than 16 years. ( 10797368 )
2000
15
Primary central nervous system leukemia with a novel chromosomal translocation. ( 9335020 )
1997
16
Central nervous system leukemia. ( 8868094 )
1996
17
Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. ( 7537120 )
1995
18
The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. ( 8319175 )
1993
19
Cerebrospinal fluid neopterin levels in children with central nervous system leukemia. ( 8348070 )
1993
20
Tumor necrosis factor in the cerebrospinal fluid of children with central nervous system leukemia. ( 1901928 )
1991
21
Temporal bone findings in central nervous system leukemia. ( 1812774 )
1991
22
Effective prevention of central nervous system leukemia with intrathecal methotrexate and intrathecal methotrexate, cytosine arabinoside, and hydrocortisone in childhood acute lymphocytic leukemia. ( 2323651 )
1990
23
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. ( 3052630 )
1988
24
Central nervous system leukemia. ( 3047654 )
1988
25
Intermittent central nervous system irradiation and intrathecal chemotherapy for central nervous system leukemia in children. ( 3624023 )
1987
26
Elevation of cerebrospinal fluid sialic acid concentration in children with central nervous system leukemia. ( 3296627 )
1987
27
Significance of cerebrospinal fluid ferritin estimation in central nervous system leukemia. ( 3113843 )
1987
28
Pickwickian syndrome related to central nervous system leukemia. ( 3458358 )
1986
29
Millipore filter vs cytocentrifuge for detection of childhood central nervous system leukemia. ( 2425776 )
1986
30
The central nervous system leukemia: a clinical and pathological study. ( 3860195 )
1985
31
A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). ( 3857943 )
1985
32
Central nervous system leukemia in children with acute nonlymphoblastic leukemia. ( 3840394 )
1985
33
Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. ( 6366149 )
1984
34
Intrathecal methotrexate versus central nervous system leukemia. ( 6399986 )
1984
35
Recognition of central nervous system leukemia by flow cytometry. ( 6596184 )
1984
36
Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. ( 6366138 )
1983
37
Diabetes insipidus associated with central nervous system leukemia. ( 7123345 )
1982
38
Aziridinylbenzoquinone (AZQ) treatment of central nervous system leukemia. ( 6958367 )
1982
39
Central nervous system leukemia and lymphoma: computed tomographic manifestations. ( 6976091 )
1981
40
Scanning electron microscopic study on central nervous system leukemia in children. ( 292293 )
1979
41
Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. ( 288969 )
1979
42
Cerebrospinal fluid polyamine monitoring in central nervous system leukemia. ( 852128 )
1977
43
Antimetaboliths in the prophylaxis and treatment of central nervous system leukemia. ( 267507 )
1977
44
Central nervous system leukemia. ( 267618 )
1977
45
Central nervous system leukemia in childhood. ( 927864 )
1977
46
The value of maintenance therapy following treatment of central nervous system leukemia. ( 332318 )
1977
47
Adult central nervous system leukemia: incidence and clinicopathologic features. ( 822517 )
1976
48
Complications of intrathecal methotrexate prophylaxis and treatment of central nervous system leukemia in children. ( 1071901 )
1976
49
Preventing central nervous system leukemia. ( 990041 )
1976
50
Central nervous system leukemia. ( 1094335 )
1975

Variations for Central Nervous System Leukemia

Expression for Central Nervous System Leukemia

Search GEO for disease gene expression data for Central Nervous System Leukemia.

Pathways for Central Nervous System Leukemia

Pathways related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.44 CD19 MME
2 11.42 CD19 PBX1 RUNX1 RUNX1T1
3 11.39 PBX1 RUNX1 RUNX1T1
4 11.31 CD19 MME
5 11.14 CD19 MME
6 10.88 CD19 MME

GO Terms for Central Nervous System Leukemia

Sources for Central Nervous System Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....